

**CIGNA GLOBAL INSURANCE COMPANY LIMITED**  
**(a Guernsey Company)**

**Annual Report and Financial Statements**

**For the year ended 31 December 2019**

<b>CONTENTS</b>	<b>PAGE</b>
Management and Administration	1
Report of the Directors	2 - 3
Independent Auditor's Report	4 – 5
Balance Sheet	6
Statement of Comprehensive Income	7
Statement of Changes in Total Equity	8
Statement of Cash Flows	9
Notes to the Financial Statements	10 - 16

**MANAGEMENT AND ADMINISTRATION**

**DIRECTORS:**

M J Cutts-Watson  
P P Greskoff (resigned 5 December 2019)  
S Hasle (resigned 23 April 2020)  
M Santanello (appointed 25 July 2019)  
B Reynders (appointed 23 April 2020)  
A L Watt

**REGISTERED OFFICE:**

Mill Court  
La Charroterie  
St. Peter Port  
Guernsey GY1 4ET

**SECRETARY AND GENERAL REPRESENTATIVE:**

Marsh Management Services Guernsey Limited  
Mill Court  
La Charroterie  
St. Peter Port  
Guernsey GY1 4ET

**INDEPENDENT AUDITOR:**

PricewaterhouseCoopers CI LLP  
PO Box 321  
Royal Bank Place  
1 Glatigny Esplanade  
St Peter Port  
Guernsey GY1 4ND

**REPORT OF THE DIRECTORS (CONTINUED)  
FOR THE YEAR ENDED 31 DECEMBER 2019**

The Directors of the Company present their annual report and the audited financial statements for the year ended 31 December 2019.

**Structure of Company & Principal Activities**

The Company was incorporated on 21 May 2004 in accordance with the provisions of The Companies (Guernsey) Law, 2008 and licensed under The Insurance Business (Bailiwick of Guernsey) Law, 2002 to carry on general insurance business, excluding domestic business.

**Results**

The results for the year are shown in the statement of comprehensive income on page 7.

**Dividends**

The Directors did not declare a dividend during the year (2018: Nil).

**Directors**

The Directors of the Company during the year and as at 31 December 2019 were as stated on page 1.

**Secretary**

The secretary of the Company during the year and as at 31 December 2019 was Marsh Management Services Guernsey Limited.

**Insurance Manager**

The management of the Company is delegated to Marsh Management Services Guernsey Limited and other parties within the Cigna Corporation.

**Going concern**

As detailed further in note 13, the Directors have considered the impact of COVID-19, and are of the opinion that Company's financial statements for 2019 are not impacted

The accounts have been prepared on a going concern basis. The directors believe that this basis is appropriate as the Company has net assets in excess of its regulatory solvency requirement, is not dependent on any external finance and is expected to continue to operate profitably in the foreseeable future.

**Share capital**

As detailed further in note 8, additional share capital was issued during the year.

**Directors' Responsibilities**

The Directors are required to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the Company and of the Profit or Loss of the Company for that period and are in accordance with applicable Guernsey law and accounting principles generally accepted in the United States of America ("US GAAP"). In preparing these financial statements, the Directors are required to:

1. Select suitable accounting policies and apply them consistently;
2. Make judgments and estimates that are reasonable and prudent;
3. State whether applicable accounting standards have been followed subject to any material departures disclosed and explained in the financial statements; and
4. Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors confirm they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and The Insurance Business (Bailiwick of Guernsey) Law, 2002. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**REPORT OF THE DIRECTORS (CONTINUED)  
FOR THE YEAR ENDED 31 DECEMBER 2019**


**Auditors and disclosure of information to auditors**

In accordance with Section 249 of The Companies (Guernsey) Law 2008, the Directors confirm that:

- so far as the Directors are aware, there is no relevant audit information of which the Company's auditor is unaware; and
- the Directors have taken all the steps that he/ she ought to have taken as a Director in order to make him/ herself aware of any relevant audit information and to establish that the Company's auditor is aware of that information; and
- the information given in the Report of the Directors is consistent with the financial statements.

**Independent Auditor**

A resolution for the reappointment of PricewaterhouseCoopers CI LLP as auditor of the Company is to be proposed at the forthcoming Annual General Meeting.



.....  
Director

Date: 3/8/20,

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CIGNA GLOBAL INSURANCE COMPANY LIMITED**

## **Report on the audit of the financial statements**

---

### **Our opinion**

In our opinion, the financial statements give a true and fair view of the financial position of Cigna Global Insurance Company Limited (the "company") as at 31 December 2019, and of its financial performance and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America and have been properly prepared in accordance with the requirements of The Companies (Guernsey) Law, 2008 and The Insurance Business (Bailiwick of Guernsey) Law, 2002.

### **What we have audited**

The company's financial statements comprise:

- the balance sheet as at 31 December 2019;
- the statement of comprehensive income for the year then ended;
- the statement of changes in total equity for the year then ended;
- the statement of cash flows for the year then ended; and
- the notes to the financial statements, which include a description of the significant accounting policies.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing ("ISAs"). Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Independence**

We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants ("IESBA Code") and with SEC Independence Rules. We have fulfilled our other ethical responsibilities in accordance with the IESBA Code.

### **Other information**

The directors are responsible for the other information. The other information comprises all the information included in the Annual Report and Financial Statements but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Responsibilities of the directors for the financial statements**

The directors are responsible for the preparation of the financial statements that give a true and fair view in accordance with accounting principles generally accepted in the United States of America, the requirements of Guernsey law and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CIGNA GLOBAL INSURANCE COMPANY LIMITED (CONTINUED)**

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

---

**Use of this report**

This independent auditor's report, including the opinions, has been prepared for and only for the members as a body in accordance with Section 262 of The Companies (Guernsey) Law, 2008 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

---

**Report on other legal and regulatory requirements**

Under The Companies (Guernsey) Law, 2008 we are required to report to you if, in our opinion:

- we have not received all the information and explanations we require for our audit;
- proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records.

We have no exceptions to report arising from this responsibility.



PricewaterhouseCoopers CI LLP  
Chartered Accountants  
Guernsey, Channel Islands  
4 August 2020

The maintenance and integrity of the company's website is the responsibility of the directors; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may have occurred to the financial statements since they were initially presented on the website.

Legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**CIGNA GLOBAL INSURANCE COMPANY LIMITED**

**BALANCE SHEET  
AT 31 DECEMBER 2019**

	Notes	31 December 2019 \$	31 December 2018 \$
<b>ASSETS</b>			
Cash and cash equivalents		37,394,726	52,713,525
Fixed deposits		40,000,000	-
Premium receivable		14,974,570	24,964,207
Accounts receivable & prepaid expenses	3	9,789,824	4,905,465
Receivable from reinsurers		1,106,948	813,141
Due from other group companies		551,888	-
Reinsurance claims reserves	6	23,105,691	19,720,328
Ceded unearned premium reserve	6	7,982,755	4,894,987
<b>TOTAL ASSETS</b>		<b>134,906,402</b>	<b>108,011,653</b>
<b>LIABILITIES</b>			
Outstanding loss reserve	6	6,750,817	6,413,748
IBNR reserve	6	25,746,123	18,985,094
Deposits received from reinsurers		27,062,428	24,540,725
Unearned premium reserve	6	16,012,667	9,215,431
<b>TOTAL INSURANCE LIABILITIES</b>		<b>75,572,035</b>	<b>59,154,998</b>
Owed to other group companies	10	-	3,061,535
Intra-group loan	7,10	-	6,000,000
Accrued expenses & other liabilities	4	4,036,189	5,368,375
<b>TOTAL LIABILITIES</b>		<b>79,608,224</b>	<b>73,584,908</b>
<b>Capital and reserves:</b>			
Equity share capital	8	38,500,000	23,500,000
Retained earnings		16,798,178	10,926,745
<b>TOTAL SHAREHOLDERS EQUITY</b>		<b>55,298,178</b>	<b>34,426,745</b>
<b>TOTAL LIABILITIES AND EQUITY</b>		<b>134,906,402</b>	<b>108,011,653</b>

The financial statements on pages 6 to 16 were approved by the Board of Directors on *23 April* 2020 and signed on its behalf by:

Director *M. Cutts-Walsh*  
*3/8/20*

STATEMENT OF COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 31 DECEMBER 2019

		31 December 2019	31 December 2018
	Notes	\$	\$
<b>INCOME</b>	2		
Gross premiums written		210,944,253	189,031,237
Reinsurance premium		(156,759,701)	(150,695,630)
Movement in unearned premium reserve		(6,797,236)	(3,331,037)
Movement in ceded unearned premium reserves		3,087,768	2,106,373
Ceding commissions		28,548,579	22,676,186
Premium fees		963,724	1,948,269
Broker fees		(9,367,076)	(8,885,689)
Fronting fees		1,226,724	-
Investment income		347,786	161,225
<b>Total income</b>		<b>72,194,821</b>	<b>53,010,934</b>
<b>EXPENSES</b>	2		
Claims paid		(150,033,890)	(145,972,343)
Claims recoverable from reinsurers		122,991,450	121,191,662
Movement in IBNR reserve		(6,761,029)	1,092,881
Movement in outstanding loss reserve		(337,069)	214,282
Movement in reinsurance claims reserves		3,385,363	(917,220)
Interest on deposits held for reinsurers		(348,930)	(398,853)
Intra-group loan interest	7,10	(76,584)	(5,100)
Management fees	10	(91,776)	(72,306)
Directors' fees		(31,980)	(15,325)
Registration/filing fees		(10,738)	(10,855)
Bank charges		(840,543)	(479,564)
Loss on foreign exchange		(211,041)	(664,534)
Allocation of group expenses		(33,363,019)	(26,183,221)
<b>Total operating expenses</b>		<b>(65,729,786)</b>	<b>(52,220,496)</b>
<b>TOTAL COMPREHENSIVE INCOME BEFORE TAX</b>		<b>6,465,035</b>	<b>790,438</b>
Income tax	2,5	(593,602)	(305,169)
<b>TOTAL COMPREHENSIVE INCOME</b>		<b>5,871,433</b>	<b>485,269</b>

The accompanying notes on pages 10 – 16 form an integral part of the financial statements.

STATEMENT OF CHANGES IN TOTAL EQUITY  
FOR THE YEAR ENDED 31 DECEMBER 2019

	<b>31 December 2019</b>	<b>31 December 2018</b>
	<b>\$</b>	<b>\$</b>
<b>Total equity at beginning of year</b>	34,426,745	33,941,476
<b>Movement in total equity resulting from operations</b>		
Total comprehensive income	5,871,433	485,269
<b>Net increase in total equity resulting from operations</b>	<u>5,871,433</u>	<u>485,269</u>
Increase in share capital	15,000,000	-
<b>Net increase in total equity</b>	20,871,433	485,269
<b>Total equity at end of year</b>	<u>55,298,178</u>	<u>34,426,745</u>
<b>Shareholders' equity per ordinary share</b>	<u><b>1.4363</b></u>	<u><b>1.4124</b></u>
<b>Number of ordinary shares issued</b>	<u>38,500,000</u>	<u>24,375,000</u>

The accompanying notes on pages 10 – 16 form an integral part of the financial statements.

**STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

	<b>31 December 2019</b>	<b>31 December 2018</b>
	<b>\$</b>	<b>\$</b>
<b>Cash flows from operating activities</b>		
Profit before tax	6,465,035	790,438
Adjustments to reconcile increase in net assets resulting from operations to net cash from/(used in) operating activities:		
Decrease/(Increase) in premium receivable	9,989,637	(2,605,569)
Decrease/(Increase) in debtors & prepaid expenses	(4,884,359)	(1,815,114)
(Increase)/decrease in reinsurance claims reserves	(3,385,363)	917,219
(Increase) in receivable from reinsurers	(293,807)	1,420,908
(Decrease)/increase in owed to other group companies	(9,613,423)	5,877,016
Increase in deposits received from reinsurers	2,521,703	8,376,024
(Decrease)/increase in accrued expenses	(1,332,186)	1,615,645
Increase/(decrease) in outstanding loss reserve	337,069	(214,282)
(Decrease) in IBNR reserve	6,761,029	(1,092,881)
Increase in unearned premium reserve	6,797,236	3,331,037
(Increase)/decrease in ceded unearned premium reserve	(3,087,768)	(2,106,372)
Investment income	-	(161,244)
Income tax	(593,602)	(305,169)
<b>Net cash from operating activities</b>	<b>9,681,201</b>	<b>14,027,656</b>
<b>Cash flows from in investment activities</b>		
Sale of investments	-	8,877,508
(Purchase)/sale of fixed deposit	(40,000,000)	10,009,667
	(40,000,000)	18,887,175
<b>Cash flows from financing activities</b>		
Increase in share capital	15,000,000	-
<b>Net (decrease)/increase in cash</b>	<b>(15,318,799)</b>	<b>32,914,831</b>
<b>Cash and cash equivalents at beginning of year</b>	<b>52,713,525</b>	<b>19,798,694</b>
<b>Cash and cash equivalents at end of year</b>	<b>37,394,726</b>	<b>52,713,525</b>

The accompanying notes on pages 10 – 16 form an integral part of the financial statements.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

**1. ORGANISATION**

CIGNA Global Insurance Company Limited (the “Company”), a wholly owned subsidiary of Cigna Holdings Overseas Inc. (the “Parent”), which is a wholly-owned subsidiary of Cigna Global Reinsurance Company Limited (“CGRC”), which in turn is wholly owned by Cigna Global Holdings, Inc, which is an indirect wholly-owned subsidiary of Cigna Corporation (“Cigna”).

The Company was incorporated in Guernsey on 21 May 2004 and is a Guernsey registered insurance company under The Companies (Guernsey) Law, 2008.

The Company acts as a principal insurer of the insured risks in relation to policies issued by various business lines within the CIGNA group and companies under the strategic management of a global insurance operation.

On December 20, 2018, Cigna acquired Express Scripts through a series of mergers (collectively, the “Merger”).

Cigna Holding Company (formerly named Cigna Corporation and referred to as “Old Cigna”) and Express Scripts each merged with and into a wholly-owned subsidiary of Cigna. As a result of these transactions, Cigna became the parent of the combined company. The acquired Express Scripts business accelerates Cigna’s strategy by greatly increasing the Company’s ability to put medicine within reach of customers and also making health care more affordable, predictable and simple.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Basis of presentation***

These financial statements have been prepared on a going concern and accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (GAAP).

These financial statements were prepared in conformity with GAAP. Amounts recorded in the financial statements necessarily reflect management’s estimates and assumptions about medical costs, investment valuation, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of change in estimate is generally included in earnings in the period of adjustment.

The Company’s financial statements are presented in USD which is the functional and the reporting currency of the Company.

***Critical accounting estimates***

The preparation of the financial statements in accordance with GAAP requires management to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if:

- It requires assumptions to be made that were uncertain at the time the estimate was made; and
- Changes in the estimate or different estimates that could have been selected could have a material effect on the Company’s results of operations or financial condition.

Management believes the current assumptions used to estimate amounts reflected in the Company’s financial statements are appropriate. However, if actual experience differs from the assumptions used in estimating amounts reflected in the financial statements, the resulting changes could have a material adverse effect on the Company’s results of operations and, in certain situations, could have a material adverse effect on its liquidity and financial condition.

***Cash and cash equivalents***

Cash comprises bank balances with banks and financial institutions. Cash balances are carried at the notional value which equates to fair value. Foreign balances are converted to USD at the prevailing spot rate. All cash balances are readily accessible within 24 hours without penalty.

***Fixed deposits***

Fixed deposits include fixed term bank deposits with an initial term of more than three months which cannot be withdrawn before maturity without penalty.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

***Financial instruments***

In the normal course of business, the Company enters into transactions involving various types of financial instruments, including investments such as bonds. The fair value of these instruments may change due to interest rate and market fluctuations, and most have credit risk.

***Bonds***

Bonds include municipal bonds, corporate notes, U.S. Treasury securities, federal agency mortgage-backed securities and other asset-backed securities. These investments are classified as available-for-sale and are carried at fair value with changes in fair value recorded in accumulated other comprehensive income, net of applicable income taxes, within shareholders' equity. Because bonds are available for use in current operations, they are classified as current assets without regard to their contractual maturity dates.

***Investment gains and losses***

Realised investment gains and losses result from sales, investment asset write-downs, and changes in valuation reserves, based on specifically identified assets. Unrealised gains and losses on bonds carried at fair value are included in accumulated other comprehensive income, net of deferred taxes.

***Premiums***

Premium income and reinsurance premium payable, net of premium taxes, if any, are accounted for on an accruals basis.

Gross premiums written and reinsurance premiums payable comprise the premiums on contracts entered during the year irrespective of whether they relate in whole or part to a later accounting year. Premiums collected on a monthly and quarterly basis are not annualised. Provision is made, as appropriate, for unearned premium and unexpensed reinsurance premium, if any. Unearned premium is that proportion of premium written in a year that relates to periods of risk after the balance sheet date. Unearned premiums are calculated on a time apportionment basis.

***Reinsurance premium***

Reinsurance premium is bought into the underwriting account on an accruals basis. The proportion of any premium unexpensed at the balance sheet date is carried forward as an unearned reinsurance premium balance.

***Investment income***

Investment income represents interest receivable on deposits and realised and unrealised gains on investments. Interest receivable is included on an effective interest rate basis.

***Expenses***

Expenses are accounted for on an accruals basis.

***Claims reserving***

Claims reserves comprise provisions for the estimated cost of settling all claims incurred up to but not paid at the balance sheet date whether reported or not.

The level of the provision has been set on the basis of the information which is currently available, including potential loss claims which have been intimated to the Company, experience of the development of similar claims and case law.

Whilst the Directors consider that the provision for these claims is fairly stated on the basis of the information currently available to them, the ultimate liability may vary as a result of subsequent information and events and may result in significant adjustments to the amount provided. Adjustments to the amounts of the provision are reflected in the financial statements in the accounting year in which the adjustments are made. Provision is made for reinsurance recoveries on a similar basis.

***Interest on deposits received from reinsurers***

Interest is payable to reinsurers on deposits which the Company holds on their behalf. Interest payable is included on an accruals basis.

***Recharge of group overheads***

Services are provided to the Company by other group companies under various contractual agreements and direct costs may be recharged to the Company as appropriate. In addition, charges incurred centrally by CIGNA Corporation Inc. are allocated to Connecticut General Life Insurance Company, CIGNA Worldwide Insurance Company and to the Company on the basis of the entities' net premiums written relative to the total net premiums written. A proportion of such overheads are recharged to reinsurers under the relevant reinsurance agreements.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

**Reinsurance**

Reinsurance is ceded primarily to limit losses from large exposures and to permit recovery of a portion of direct losses. Reinsurance does not relieve the originating insurer of liability.

Under various reinsurance agreements, the Company reinsures a proportion of the risks underwritten, one of which is Cigna Global Reinsurance Company Limited. The amount reinsured varies from contract to contract. Gross claims paid are shown in the Statement of Comprehensive Income. Amounts recoverable from reinsurers are recognised in the Balance Sheet as the relevant proportion of claims paid and payable less the amounts already received. The movement in reinsurance recoveries is shown in the Statement of Comprehensive Income. Deposits may be received from reinsurers in order to fund claims payments. These are shown as a liability in the Balance Sheet.

**Foreign currency transactions**

Financial assets and liabilities denominated in foreign currencies are translated to US Dollars at the rates of exchange ruling at the balance sheet date. Other transactions are translated at the actual rate on the date of transactions. Foreign exchange differences are reported in the Statement of Comprehensive Income.

**Taxation**

The Company is taxed at the standard rate of tax in Guernsey of 0%.

The Company is resident in the United States for tax purposes and is liable for US income tax. The Company and its Parent are included in the consolidated United States federal income tax return filed by Cigna. The Company's tax liability is calculated and paid centrally and recharged to the Company. Pursuant with a tax sharing agreement with Cigna, the provision for federal income tax is computed as if the Company is filing separate federal income tax returns, except that benefits arising from tax credits and net operating losses are allocated to those subsidiaries producing such attributes only to the extent they have been utilised in the consolidated federal income tax provision. Deferred income taxes and benefits are generally recognised when assets and liabilities have different values for financial statement and tax reporting purposes. See Note 5 for additional information.

**Recent Relevant Accounting Pronouncements**

No new Accounting Standards Updates ("ASU") were adopted from 1 January 2019.

**Accounting Guidance Not Yet Adopted**

**ASU 2016-13 – (Measurement of Credit Losses on Financial Instruments)**

The FASB issued guidance that requires a new approach using expected credit losses to estimate and recognise credit losses for certain financial instruments such as mortgage loans, reinsurance recoverables and other receivables. We expect to adopt the standard as of January 1, 2020.

3. ACCOUNT RECEIVABLE AND PREPAID EXPENSES

	31 December 2019	31 December 2018
	\$	\$
US Trust Account (see note below)	5,496,361	-
Commissions receivable	284,151	38,986
Prepayment – Grand United	681,306	663,679
US tax refund	225,321	1,090,002
Other taxes payable	489,022	184,192
Deferred acquisition costs	899,993	220,373
Deferred broker fees	1,592,149	794,191
Accrued interest	75,012	-
Unapplied cash	46,509	1,914,042
	9,789,824	4,905,465

During the year, the Company was approved as a non-admitted insurer by the National Association of Insurance Commissioners (NAIC). In accordance with the NAIC's requirements a US Trust Accounts was established and this balance is held in trust at US Bank.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019

4. ACCRUED EXPENSES & OTHER LIABILITIES

	31 December 2019	31 December 2018
	\$	\$
Audit fees	92,729	88,244
Reinsurance premium due	588,976	526,030
Premium taxes due	-	750,884
Commissions payable	1,543,461	1,969,620
Other payables	614,618	991,437
Experience rating refunds	1,196,405	1,006,479
Losses payable	-	30,581
Intra-group loan interest	-	5,100
	<u>4,036,189</u>	<u>5,368,375</u>

5. INCOME TAXES

The Company is taxed at the standard rate of tax in Guernsey of 0%.

5 (a) Income taxes receivable:

In keeping with the provisions of Section 953(d) of the Internal Revenue Code, CGIC agreed to be treated as a domestic corporation for United States tax purposes. As a result, CGIC is included in the consolidated United States federal income tax return that Cigna (CGIC's ultimate parent) files. In accordance with a tax sharing agreement, the income tax provision is computed as if each company was filing a separate income tax return. The only exception to this are benefits arising from foreign credits and net operating and capital losses which are allocated to those subsidiaries producing such attributes to the extent they are utilized in Cigna's consolidated federal income tax provision.

Below is a summary of the change in CGIC's income tax receivable for the years ended 31 December 2019 and 2018:

	31 December 2019	31 December 2018
	\$	\$
<b>Change in income taxes receivable:</b>		
Balance, beginning of period due from Cigna Corp.	689,956	665,387
Current tax provision	(1,481,878)	(448,125)
Payments	(271,079)	472,694
Balance, end of period due from Cigna Corp.	<u>(1,063,001)</u>	<u>689,956</u>

5 (b) Deferred income taxes:

Deferred income taxes are generally recognised when assets and liabilities have different values for financial statement and tax reporting purposes. These differences primarily result from CGIC's insurance operations.

Below is the summary of the change in the net deferred tax asset balance for the years ended 31 December 2019 and 2018:

	31 December 2019	31 December 2018
	\$	\$
<b>Change in net deferred tax liability:</b>		
Balance, beginning of period	400,046	257,090
Current tax provision	888,276	142,956
Balance, end of period	<u>1,288,322</u>	<u>400,046</u>

The tax effect of the temporary differences that create deferred income tax assets as of 31 December 2019 and 2018 is as follows:

	31 December 2019	31 December 2018
	\$	\$
<b>Deferred tax assets:</b>		
Other Insurance and contract holder liability	510,163	400,046
Deferred income From Foreign Operations	967,158	-
Total Deferred Tax Assets	<u>1,477,321</u>	<u>400,046</u>

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019

5. INCOME TAXES (CONTINUED)

The tax effect of the temporary differences that create deferred income tax liability as of 31 December 2019 and 2018 is as follows:

	31 December 2019	31 December 2018
<b>Deferred tax liabilities:</b>	<b>\$</b>	<b>\$</b>
Policy acquisition expenses	188,899	-
Total deferred tax liabilities	<u>188,899</u>	<u>-</u>
<b>Total net deferred tax assets/(liabilities)</b>	<b><u>1,288,322</u></b>	<b><u>400,046</u></b>

The provision for federal and foreign income taxes incurred is different from what would be obtained by applying the statutory Federal income tax rate to income before income taxes. Significant items that drive this difference are as follows:

	31 December 2019	
<b>Items:</b>	<b>\$</b>	
Provision computed at statutory rate	1,357,657	21.00%
Effect of US tax reform legislation	-	0.00%
Health Insurance Industry tax	203,103	3.14%
Prior year true up and other adjustments	<u>(967,158)</u>	<u>-14.96%</u>
<b>Total statutory income taxes</b>	<b><u>593,602</u></b>	<b><u>9.18%</u></b>

The statute of limitations for Cigna's consolidated income tax returns through 2015 have closed, and there are no pending examinations. Cigna has filed an amended consolidated tax returns for various years and the pending refund is subject to Internal Revenue Service (IRS) review. The IRS has examined Express Scripts' ("ESI") tax returns for 2010 through 2012 for which there is a significant disputed tax matter, and currently under examination for 2013 through 2015. No material impacts are anticipated for the Company.

In management's opinion, the Company has adequate tax liabilities to address potential exposures involving tax positions the Company has taken that may be challenged by the IRS upon audit. These liabilities could be revised in the near term if estimates of Cigna's ultimate liability change as a result of new developments or a change in circumstances. No material contingent tax liability is included in the Company's current federal income tax payable. The Company does not expect a significant increase in federal or foreign contingent tax liability within the next twelve months.

6. MOVEMENT IN INSURANCE LIABILITIES AND REINSURANCE ASSETS

6 (a) Claims and loss expenses

	2019			2018		
	Gross	Reinsurance	Net	Gross	Reinsurance	Net
<b>Year ended 31 December</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
Notified claims	6,413,748	(4,979,802)	1,433,946	6,628,030	(5,121,930)	1,506,100
Incurred but not reported	18,985,094	(14,740,526)	4,244,568	20,077,975	(15,515,618)	4,562,357
<b>Total at beginning of year</b>	<b>25,398,842</b>	<b>(19,720,328)</b>	<b>5,678,514</b>	<b>26,706,005</b>	<b>(20,637,548)</b>	<b>6,068,457</b>
Claims paid in the year	(150,033,890)	122,991,450	(27,042,440)	(145,972,343)	121,191,662	(24,780,681)
Increase/(decrease) in liabilities:						
- Arising from prior year claims	21,758,549	(10,114,397)	11,644,152	13,612,982	(9,407,096)	4,205,886
- Arising from current year claims	135,373,439	(116,262,416)	19,111,023	131,052,198	(110,867,346)	20,184,852
<b>Total at end of year</b>	<b>32,496,940</b>	<b>(23,105,691)</b>	<b>9,391,249</b>	<b>25,398,842</b>	<b>(19,720,328)</b>	<b>5,678,514</b>
Notified claims	6,750,817	(4,799,907)	1,950,910	6,413,748	(4,979,802)	1,433,946
Incurred but not reported	25,746,123	(18,305,784)	7,440,339	18,985,094	(14,740,526)	4,244,568
<b>Total at end of year</b>	<b>32,496,940</b>	<b>(23,105,691)</b>	<b>9,391,249</b>	<b>25,398,842</b>	<b>(19,720,328)</b>	<b>5,678,514</b>

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019

6. MOVEMENT IN INSURANCE LIABILITIES AND REINSURANCE ASSETS (CONTINUED)

6 (b) Provisions for unearned premiums

	2019			2018		
	Gross	Reinsurance	Net	Gross	Reinsurance	Net
Year ended 31 December	\$	\$	\$	\$	\$	\$
Total at beginning of year	9,215,431	(4,894,987)	4,320,444	5,884,394	(2,788,614)	3,095,780
Increase in period	16,012,667	(7,982,755)	8,029,912	9,215,431	(4,894,987)	4,320,444
Release in period	(9,215,431)	4,894,987	(4,320,444)	(5,884,394)	2,788,614	(3,095,780)
<b>Total at end of year</b>	<b>16,012,667</b>	<b>(7,982,755)</b>	<b>8,029,912</b>	<b>9,215,431</b>	<b>(4,894,987)</b>	<b>4,320,444</b>

7. INTRA-GROUP LOAN

On 19 December 2018 the Company entered into an agreement with Cigna Holdings, Inc. to borrow a line of credit of \$6 million. The loan has a maximum duration of 12 months with interest being charged daily at a commercial rate. This loan was repaid in full during the year.

8. SHAREHOLDERS' EQUITY

The authorised share capital of the Company is represented by an unlimited number of Ordinary Shares of no par value which are denominated in USD.

The holders of Ordinary Shares are entitled to:

- receive and participate in any dividends or other distributions out of the profits of the Company available for dividend or distribution;
- the right to the surplus assets remaining after payment of all the creditors of the Company in the case of winding up; and
- the right to receive notice of, and to attend and vote at, general meetings of the Company and each holder of Ordinary Shares being present in person or by attorney at a meeting upon a show of hands has one vote and upon a poll each such holder present in person or by proxy or by attorney has one vote in respect of each share held by him.

Issued capital:

31 December 2019

	Number of Ordinary Shares	\$
Ordinary Shares at 1 January 2019	24,375,000	23,500,000
Shares issued during the year	14,125,000	15,000,000
Ordinary Shares outstanding at 31 December 2019	<u>38,500,000</u>	<u>38,500,000</u>

No shares were issued or repurchased by the Company during the year.

31 December 2018

	Number of Ordinary Shares	\$
Ordinary Shares at 1 January 2018	24,375,000	23,500,000
Ordinary Shares outstanding at 31 December 2018	<u>24,375,000</u>	<u>23,500,000</u>

9. RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS

As a result of its investment strategy, the Company is also exposed to varying degrees of market risk, credit risk and liquidity risk.

a) Market Risk

Market risk is the risk that the value of the Company's investments will fluctuate due to changes in interest rates, currency rates and other market factors. Price risk embodies not only the potential for loss but also the potential for gain. Market risk also reflects that investments in unlisted companies are further subject to the limitations of fair value as a measurement device.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2019**

**9. RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (CONTINUED)**

***b) Credit Risk***

Credit risk is represented by the possibility that counterparties or exchanges will not perform under the terms of contracts agreed to with the Company. Cash and deposits are held with various banking counterparties. Credit risk includes the potential for covenant violations and possible repercussions therefrom of underlying debt instruments owned by investee companies. This also includes the potential of investee companies not meeting scheduled principal and interest payments.

The Company continuously monitors the credit standing of its counterparties and does not expect any material losses.

***c) Liquidity Risk***

Liquidity risk is the risk that the Company may encounter as a result of its inability to sell its investments quickly at fair value. It also includes the risk of not meeting unscheduled demands from vendors and third parties. The Company is able to meet its liquidity requirements by only holdings cash and cash equivalents.

**10. RELATED PARTIES**

The total remuneration paid to the independent non-executive director during the year amounted to \$31,980 (2018: \$15,325).

Total fees paid to the Company's Insurance Manager during the year totalled \$91,776 (2018: \$72,306).

Total intra-group loan interest of \$76,584 has been paid to Cigna Holdings, Inc during the year.

Various amounts are owed to and from other group companies. At the year-end a net amount of \$551,888 was owed to the Company (2018: \$3,061,535 owed to other group companies).

**11. COMPARATIVE FIGURES**

Comparative figures used in these financial statements are for the year ended 31 December 2018 for the Balance Sheet, the Statement of Comprehensive Income, the Statement of Changes in Total Equity and the Statement of Cash Flows.

**12. COMMITMENTS AND CONTINGENCIES**

In the normal course of business, the Company may enter into contracts that provide general indemnifications. The Company's maximum exposure under these arrangements is unknown as this would be dependent on future claims that may be made against the Company. The risk of material loss from such claims is considered remote.

**13. SUBSEQUENT EVENTS**

Except for the below, there have been no other significant events between the reporting date and the date of approval of these financial statements which would require a change to or disclosure in the financial statements.

**COVID-19**

As a global health service leader, Cigna wants to support its customers and employees through the COVID-19 pandemic. Given the outbreak took place in 2020, the Company's financial statements for 2019 are not impacted. We are monitoring the current and expected future impact of the pandemic from insurance, market and operational risk perspectives.

In response to the pandemic, we have invoked our business continuity plans for our global sites and have taken actions to further increase resilience by increasing employees' ability to work from home.

We anticipate increased costs from hospitalisation claims and from our commitment to cover the cost of COVID-19 testing. Movements in financial markets could also have an impact on our investment portfolio. Cigna is well placed to weather these risks in the short-term and we do not consider these to be a threat to our solvency position. Hence we anticipate meeting our financial obligations for the foreseeable future and remain going concern. As the impact of the virus continues to grow, we expect the situation will continue to develop. We will continue to monitor this closely and take further mitigating measures where necessary.